Growing clinical evidence with the ACURATE neo™ TAVI System

Sponsored by Boston Scientific

Summary: Join S. Redwood, S. Toggweiler and H. Moellmann as they

  • Discuss the advantages of the ACURATE neo™ intuitive and predictable implantation procedure with a unique “top-down” deployment
  • Highlight the latest clinical data from the 1-Year follow-up of the SAVI-TF 1000 global registry1

Key findings SAVI-TF 1000 registry1

Symetis ACURATE neo™ Valve Implantation using Transfemoral Access

  • Confirmed long-term safety, clinical efficacy and valve performance of the ACURATE neo™ TAVI System in an all-comers, high-risk TAVI population
  • Outstanding procedural success, survival, and NYHA development
  • Minimal PVL and lowest new pacemaker rates in TAVI


1 Möllmann, H. et al.: 1-year outcomes of 1000 patients enrolled in the SAVI-TF registry; presented at EuroPCR 2017
2 Möllmann, H. et al.: Acute/ 30-Day results of 1000 patients enrolled in the SAVI-TF registry; presented at EuroPCR 2017


All cited trademarks are the property of their respective owners.


The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labelling supplied with each device. Information for use only in countries with applicable health authority registrations. Material not intended for use or distribution in France, Japan and the USA.

SH-480501-AA JUN2017


Transfemoral TAVI System

ACURATE neo™ Transfemoral TAVI System



98.7% Procedural Success
98.7% Survival Rate
8.2% New Pacemaker Rate
4.1% Paravalvular Leak ≥ grade 22


View SAVI-TF EuroPCR presentation


With an unrestricted educational grant from Boston Scientific


This case report does not reflect the opinion of PCR or PCRonline, nor does it engage their responsibility.